Biosimilar Guidance Development Timelines Criticized By Docs And Patients
Executive Summary
FDA's user fee deal with sponsors sets target dates for documents on interchangeability, naming and labeling, but non-industry stakeholders urge agency to accelerate their release; guidance development efforts will get boost in BsUFA II with funding for new dedicated biosimilars unit starting in fiscal year 2018.
You may also be interested in...
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.
Biosimilar Prescribing Decisions May Depend Upon Disease State
Express Scripts’ Eichholz says clinicians may be less inclined to use a biosimilar in ‘life or death’ oncology indications compared to inflammatory diseases.